All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Study of the Effects of Risankizumab in Moderate to Severe Crohn?s Disease

Author(s): Yuan Fang*, Jipeng Li, J. Wu and Luxi Zhang
Department of Gastroenterology, Jinchang People's Hospital, Jinchang, Gansu 737100, 1Department of Orthopedics, Yongchang County People's Hospital, Jinchang, Gansu 737200, China

Correspondence Address:
Yuan Fang, Department of Gastroenterology, Jinchang People's Hospital, Jinchang, Gansu 737100, China, E-mail:

To study the effect of risankizumab in moderate to severe Crohn's disease. In the trial, 80 patients with moderate-to-severe Crohn’s disease who were hospitalized to our hospital between January 2021 and January 2022 were randomly assigned to the risankizumab group (n=40, with risankizumab added to conventional treatment) or the placebo group (n=40, with placebo added to conventional treatment) to compare the clinical efficacy, inflammatory indexes, incidence of adverse effects and quality of life of the two groups scores. The clinical remission rate and endoscopic remission rate were both higher in the risankizumab group than in the placebo group (p<0.05). After therapy, the risankizumab group had lower levels of C-reactive protein, platelet count, erythrocyte sedimentation rate, all quality of life scores, and the frequency of adverse reactions than the placebo group, while the mean platelet volume was higher than the placebo group (p<0.05). Risankizumab is effective in treating moderate to severe Crohn’s disease, relieving the inflammatory state of the body, reducing the occurrence of adverse effects and improving quality of life.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report